Comparing drug safety of hepatitis C therapies using post-market data
暂无分享,去创建一个
Jingcheng Du | Cui Tao | Jason H. Moore | Liu Yang | Xinyuan Zhang | Jiayi Tong | Yong Chen | Jing Huang | Rui Duan | R. Duan | Jing Huang | Cui Tao | Jingcheng Du | Jiayi Tong | Yong Chen | Liu Yang | J. Moore | Xinyuan Zhang
[1] Y. Miyakawa,et al. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. , 2000, Blood.
[2] Karl Pearson F.R.S.. X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling , 2009 .
[3] Terry L King. A Guide to Chi-Squared Testing , 1997 .
[4] K. Pearson. On the Criterion that a Given System of Deviations from the Probable in the Case of a Correlated System of Variables is Such that it Can be Reasonably Supposed to have Arisen from Random Sampling , 1900 .
[5] A. Bate,et al. A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.
[6] Viraj Suvarna,et al. Phase IV of Drug Development , 2010, Perspectives in clinical research.
[7] Sammy Saab,et al. Management of Hepatitis C Antiviral Therapy Adverse Effects , 2010, Current hepatitis reports.
[8] Juan M Banda,et al. A curated and standardized adverse drug event resource to accelerate drug safety research , 2016, Scientific Data.
[9] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[10] Christophe Lallemand,et al. Safety, Tolerability, and Immunogenicity of Interferons , 2010, Pharmaceuticals.
[11] Yaoyun Zhang,et al. CD-REST: a system for extracting chemical-induced disease relation in literature , 2016, Database J. Biol. Databases Curation.
[12] J. Emparanza,et al. [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.
[13] M. Alter,et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.
[14] Lauren McCormack,et al. Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial , 2015, Drug Safety.
[15] T. Alshammari,et al. Drug safety: The concept, inception and its importance in patients’ health , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[16] Stefan Sleijfer,et al. Side Effects of Interferon-α Therapy , 2005, Pharmacy World and Science.
[17] M. Denniston,et al. Awareness of infection, knowledge of hepatitis C, and medical follow‐up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001‐2008 , 2012, Hepatology.
[18] M. Fried,et al. Side effects of therapy of hepatitis C and their management , 2002, Hepatology.
[19] Yoon K Loke,et al. Drug safety assessment in clinical trials: methodological challenges and opportunities , 2012, Trials.
[20] Nicholas Moore,et al. Differences between clinical trials and postmarketing use. , 2003, British journal of clinical pharmacology.
[21] E L Murphy,et al. Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.
[22] H. Wedemeyer,et al. Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.